Q1 Earnings Estimate for Soligenix Issued By Zacks Small Cap

Soligenix, Inc. (NASDAQ:SNGX) – Stock analysts at Zacks Small Cap issued their Q1 2025 earnings per share (EPS) estimates for shares of Soligenix in a note issued to investors on Wednesday, March 26th. Zacks Small Cap analyst D. Bautz forecasts that the biopharmaceutical company will earn ($0.67) per share for the quarter. The consensus estimate for Soligenix’s current full-year earnings is ($4.65) per share. Zacks Small Cap also issued estimates for Soligenix’s Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.79) EPS and FY2027 earnings at ($1.75) EPS.

Soligenix Stock Performance

Soligenix stock opened at $2.27 on Thursday. The company’s 50 day simple moving average is $2.35 and its 200-day simple moving average is $3.08. Soligenix has a 1 year low of $1.83 and a 1 year high of $14.92. The company has a market capitalization of $5.70 million, a price-to-earnings ratio of -0.30 and a beta of 2.03.

Soligenix (NASDAQ:SNGX) last issued its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by ($0.19). The company had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.20 million. Soligenix had a negative net margin of 1,473.38% and a negative return on equity of 223.29%. During the same quarter last year, the firm posted ($12.66) earnings per share.

Institutional Trading of Soligenix

A hedge fund recently raised its stake in Soligenix stock. Geode Capital Management LLC raised its position in shares of Soligenix, Inc. (NASDAQ:SNGX) by 42.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,094 shares of the biopharmaceutical company’s stock after buying an additional 7,729 shares during the period. Geode Capital Management LLC owned about 1.04% of Soligenix worth $71,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 3.60% of the company’s stock.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.